Keymed Biosciences Inc. (SEHK: 2162)
Health Care · Biotechnology · CN
HK$78.30
-0.70% today · +15.3% 1Y
Keymed Biosciences Inc. (SEHK: 2162) operates in the Biotechnology industry within the Health Care sector. The company is valued at $2.94B and employs 1,768 people.
Over the last twelve months the share price has gained 15.3%, trading between 44.66 and 89.75.
Tweenvest scores Keymed Biosciences Inc. across four factors: quality 44/100, value 48/100. Its strongest factor is value.
2162 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $2.94B
- Revenue (TTM)
- $122.87M
- P/E
- 24.99
- EPS
- 2.71
- Dividend yield
- —
- Beta (5Y)
- -0.16
- 52-week high
- HK$89.75
- 52-week low
- HK$44.66
- Avg volume (3M)
- —
- Shares outstanding
- 294.60M
- Employees
- 1,768
- Next earnings
- —
About Keymed Biosciences Inc.
Keymed Biosciences Inc., a biotechnology firm founded in 2016 in Chengdu, China (formerly known as 2Health Biosciences, Inc.), specializes in the research and development of innovative biological treatments, primarily targeting autoimmune and oncology diseases. A cornerstone of their pipeline is CM310, their lead product candidate, which is currently being developed for the management of moderate to severe atopic dermatitis (AD), asthma, chronic rhinosinusitis with nasal polyposis (CRSwNP), and chronic obstructive pulmonary disease (COPD). Complementing this, the company is also progressing CM326, a monoclonal antibody designed to inhibit thymic stromal lymphopoietin, for similar indications such as AD, CRSwNP, asthma, and COPD. In the realm of oncology, Keymed is developing CMG901 for solid tumors, particularly those affecting the stomach and gastroesophageal junction. Another significant candidate, CM313, is a humanized monoclonal antibody slated for the treatment of relapsed or refractory multiple myeloma, lymphoma, other blood cancers, and systemic lupus erythematosus. Their extensive portfolio further includes MIL95/CM312, a humanized monoclonal antibody targeting CD47; CM338, an antagonist antibody against mannose-binding lectin-associated serine protease-2; CM355, intended for relapsed or refractory non-Hodgkin's lymphoma; CM336, for multiple myeloma; CM350, for various solid tumors; and CM369, an anti-CC chemokine receptor 8 monoclonal antibody.
- ISIN
- KYG5252B1023
- Founded
- 2016
- Listed since
- Jul 8, 2021
- Exchange
- The Stock Exchange of Hong Kong Ltd.
- Currency
- HKD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Arcus Biosciences, Inc.NYSE: RCUS | $3.11B | $24.53 | +0.49% |
| Dyne Therapeutics, Inc.NasdaqGS: DYN | $3.11B | $16.15 | -2.94% |
| Acrobiosystems Co.,Ltd.SZSE: 301080 | $3.06B | CN¥122.20 | -13.38% |
| Xiamen Amoytop Biotech Co., Ltd.SHSE: 688278 | $3.01B | CN¥50.77 | -4.01% |
| Zai Lab LimitedNasdaqGM: ZLAB | $2.81B | $24.81 | -0.72% |
| Precigen, Inc.NasdaqGS: PGEN | $2.80B | $7.74 | -0.96% |
| Yili Chuanning Biotechnology Co.,Ltd.SZSE: 301301 | $2.74B | CN¥8.22 | +0.37% |
| Bavarian Nordic A/SCPSE: BAVA | $2.69B | Dkr241.20 | +1.86% |
Figures last refreshed Oct 11, 2026.